Asteria Health recalled 133 estradiol pellets on January 26, 2026, after detecting potential metal particulate matter. The recall, classified as Class II, affects pellets with lot number 253000126 and an expiration date of June 9, 2026. Consumers must stop using the product immediately and contact their healthcare provider for guidance.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves 133 estradiol pellets manufactured by Asteria Health. The affected lot number is 253000126, expiring on June 9, 2026. The product was distributed nationwide in the United States.
The recall stems from the potential presence of metal particulate matter in the estradiol pellets. This contamination poses a serious health risk, classified as Class II, meaning use may cause temporary or medically reversible adverse health consequences.
As of the report date, there have been no reported injuries or incidents stemming from the use of the estradiol pellets. Monitoring for adverse effects continues as part of the recall process.
Consumers should stop using the estradiol pellets immediately. They are advised to contact F.H. Investments, Inc. or their healthcare provider for further guidance and to discuss possible returns.
For guidance, consumers can reach F.H. Investments, Inc. at their address: 432 Industrial Ln, Birmingham, AL 35211. Additional details can be found on the FDA's website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.